Organon & Co.
NYSE: OGN. Canonical company identity and public leadership record.
US
- Alpha ID
- alpha:company:0e08bc91-6247-4053-b645-131f0beea829
- SEC CIK
- 0001821825
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 18, 2026
- Newest evidence
- Apr 24, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Joseph MorrisseySince Feb 24, 2026
- Chair
- Not published
- Independent
- Not published10 directors published
- Published claims
- 173 distinct sources
- Evidence records
- 50 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 5 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CEO CHANGED
Joseph Morrissey executive of Organon & Co., effective 2026-02-24.
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Interim Chief Executive Officer | Joseph Morrissey | Feb 2026 | current | Source reportedE3 |
| Senior Vice President Finance Corporate Controller | Lynette Holzbaur | Feb 2026 | current | Source reportedE4 |
| Chief Financial Officer | Matthew Walsh | Feb 2026 | current | Source reportedE5 |
Board of directors
Evidence10 directors published. Independence determinations are not published for every director.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Alan Ezekowitz | Independence not published | 2021 | None published | Source reportedE2 |
| Carrie S. Cox | Independence not published | 2021 | None published | Source reportedE2 |
| Cynthia M. Patton | Independence not published | 2021 | None published | Source reportedE2 |
| Deborah Leone | Independence not published | 2021 | None published | Source reportedE2 |
| Fulcrum Therapeutics | Independence not published | 2021 | None published | Source reportedE2 |
| Philip Ozuah | Independence not published | 2021 | None published | Source reportedE2 |
| Ramona Sequeira | Independence not published | 2025 | None published | Source reportedE2 |
| Robert Essner | Independence not published | 2021 | None published | Source reportedE2 |
| Rochelle B. Lazarus | Independence not published | 2021 | None published | Source reportedE2 |
| Shalini Sharp | Independence not published | 2021 | None published | Source reportedE2 |
Committees and risk ownership
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Financials and market context
EvidenceGovernance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- CommitteesNot reviewed. Committee mandates show where oversight is delegated.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Joseph MorrisseyInterim Chief Executive Officercompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:15
- Lynette HolzbaurSenior Vice President Finance Corporate Controllercompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:16
- Matthew WalshChief Financial Officercompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:17
- Alan EzekowitzDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:5
- Carrie S. CoxDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:6
- Cynthia M. PattonDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:7
- Deborah LeoneDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:8
- Fulcrum TherapeuticsDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:9
- Philip OzuahDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:10
- Ramona SequeiraDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:11
- Robert EssnerDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:12
- Rochelle B. LazarusDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:13
- Shalini SharpDirectorcompany:0e08bc91-6247-4053-b645-131f0beea829:leadership_role:14
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 5 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 18, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 24, 2026. Retrieved Sep 2, 2026. Cited by 10 Claims.
- E3sec filing. Published Feb 24, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E4sec filing. Published Feb 24, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5sec filing. Published Feb 24, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 18, 2026- Joseph Morrissey executive of Organon & Co., effective 2026-02-24.
- Lynette Holzbaur executive of Organon & Co., effective 2026-02-24.
- Matthew Walsh executive of Organon & Co., effective 2026-02-24.
- Ramona Sequeira seat on Organon & Co., effective 2025-01-01.
- Alan Ezekowitz seat on Organon & Co., effective 2021-01-01.
- Carrie S. Cox seat on Organon & Co., effective 2021-01-01.
- Cynthia M. Patton seat on Organon & Co., effective 2021-01-01.
- Deborah Leone seat on Organon & Co., effective 2021-01-01.
- Fulcrum Therapeutics seat on Organon & Co., effective 2021-01-01.
- Philip Ozuah seat on Organon & Co., effective 2021-01-01.
- Robert Essner seat on Organon & Co., effective 2021-01-01.
- Rochelle B. Lazarus seat on Organon & Co., effective 2021-01-01.
- Shalini Sharp seat on Organon & Co., effective 2021-01-01.



